CN115667254A - 作为溴结构域蛋白质抑制剂的化合物和组合物 - Google Patents

作为溴结构域蛋白质抑制剂的化合物和组合物 Download PDF

Info

Publication number
CN115667254A
CN115667254A CN202180033928.8A CN202180033928A CN115667254A CN 115667254 A CN115667254 A CN 115667254A CN 202180033928 A CN202180033928 A CN 202180033928A CN 115667254 A CN115667254 A CN 115667254A
Authority
CN
China
Prior art keywords
methyl
ethyl
oxo
dihydro
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180033928.8A
Other languages
English (en)
Inventor
徐琰
于波
郭晶
刘湘永
王家炳
丁列明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of CN115667254A publication Critical patent/CN115667254A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供一种溴结构域抑制剂。本发明也提供包含这类化合物的组合物和制剂，及使用和制备这样的化合物的方法。

Description

PCT国内申请，说明书已公开。

Claims (46)

  1. PCT国内申请，权利要求书已公开。
CN202180033928.8A 2020-05-21 2021-05-20 作为溴结构域蛋白质抑制剂的化合物和组合物 Pending CN115667254A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/091479 2020-05-21
CN2020091479 2020-05-21
PCT/CN2021/094838 WO2021233371A1 (zh) 2020-05-21 2021-05-20 作为溴结构域蛋白质抑制剂的化合物和组合物

Publications (1)

Publication Number Publication Date
CN115667254A true CN115667254A (zh) 2023-01-31

Family

ID=78708097

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180033928.8A Pending CN115667254A (zh) 2020-05-21 2021-05-20 作为溴结构域蛋白质抑制剂的化合物和组合物

Country Status (2)

Country Link
CN (1) CN115667254A (zh)
WO (1) WO2021233371A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022268075A1 (zh) * 2021-06-21 2022-12-29 贝达药业股份有限公司 化合物在制备用于治疗骨髓纤维化及其相关症状/体征的药物中的应用、该化合物的用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081189A1 (en) * 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081203A1 (en) * 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
CN107207493A (zh) * 2014-11-10 2017-09-26 基因泰克公司 作为布罗莫结构域抑制剂的经取代的吡咯并吡啶
CN108314680A (zh) * 2017-01-16 2018-07-24 凯惠科技发展(上海)有限公司 一种含芳环化合物、其制备方法、药物组合物及应用
CN109071534A (zh) * 2016-04-15 2018-12-21 艾伯维公司 布罗莫结构域抑制剂
WO2019120234A2 (zh) * 2017-12-20 2019-06-27 贝达药业股份有限公司 作为溴结构域蛋白质抑制剂的化合物和组合物
CN110577526A (zh) * 2018-06-07 2019-12-17 上海翰森生物医药科技有限公司 溴域结构蛋白抑制剂的盐及其制备方法和应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081189A1 (en) * 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081203A1 (en) * 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
CN107207493A (zh) * 2014-11-10 2017-09-26 基因泰克公司 作为布罗莫结构域抑制剂的经取代的吡咯并吡啶
CN109071534A (zh) * 2016-04-15 2018-12-21 艾伯维公司 布罗莫结构域抑制剂
CN108314680A (zh) * 2017-01-16 2018-07-24 凯惠科技发展(上海)有限公司 一种含芳环化合物、其制备方法、药物组合物及应用
WO2019120234A2 (zh) * 2017-12-20 2019-06-27 贝达药业股份有限公司 作为溴结构域蛋白质抑制剂的化合物和组合物
CN110577526A (zh) * 2018-06-07 2019-12-17 上海翰森生物医药科技有限公司 溴域结构蛋白抑制剂的盐及其制备方法和应用

Also Published As

Publication number Publication date
WO2021233371A1 (zh) 2021-11-25

Similar Documents

Publication Publication Date Title
AU2018351400B2 (en) Dihydropyrimidine compounds and uses thereof in medicine
CN108976223B (zh) 稠合三环类化合物及其在药物中的应用
JP2020504747A (ja) ベンズイミダゾール誘導体、調製方法およびそれらの使用
AU2018290511B2 (en) Dihydropyrimidine compounds and uses thereof in medicine
CN110167941B (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
WO2020177729A1 (zh) 稠合芳香环类衍生物、其制备方法及其在医药上的应用
CN113302196A (zh) Egfr抑制剂及其组合物和应用
CN114430740A (zh) Egfr抑制剂、组合物及其制备方法
WO2020043080A1 (en) Fused tricyclic compounds and uses thereof in medicine
WO2022060951A1 (en) Compositions for modulating splicing
EP4165045A1 (en) Dual kinase-bromodomain inhibitors
CN113248497B (zh) 用作fgfr4抑制剂的稠环衍生物
US20220194951A1 (en) Dihydropyrimidine compound and application thereof as drug
CN114885607B (zh) 喹啉基膦氧化合物及其组合物和用途
CN110964023A (zh) 稠合四环类化合物及其在药物中的应用
CN115667254A (zh) 作为溴结构域蛋白质抑制剂的化合物和组合物
WO2022143610A1 (zh) 新型酰胺吡咯类化合物及其在药物中的应用
CN114430741A (zh) Egfr抑制剂、组合物及其制备方法
CN110903284B (zh) 稠合三环类化合物及其在药物中的应用
CN113493441A (zh) 新型螺环类化合物及其在药物中的应用
CN116867779A (zh) 用于癌症治疗的KRas抑制剂
CN113493453A (zh) 稠合芳香环类衍生物、其制备方法及其在医药上的应用
CN109988169B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN114075206A (zh) 新型稠环类化合物及其在药物中的应用
CN117624170A (zh) 具有抗kras突变肿瘤活性的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination